Full-Time
People Business Systems Manager
Updated on 9/4/2026
BridgeBio
1,001-5,000 employees
Develops therapies for genetic diseases
Compensation Overview
$141k - $185k/yr
San Francisco, CA, USA
Hybrid
Regular work from offices in San Francisco and Palo Alto is required; candidates must be based in the San Francisco Bay Area.
 IT Operations (1) |
|---|
Get referred to BridgeBio
See people who can refer or advise you
- 5+ years of hands-on Workday HCM administration as a named system owner or HRIS product owner in a regulated environment.
- Demonstrated Greenhouse ATS and VNDLY, or equivalent VMS, experience.
- Deep knowledge of Workday business processes, security roles, calculated fields, and EIB imports.
- Hands-on ServiceNow HRSD configuration experience.
- SOX ITGC compliance experience with named control ownership.
- Proven ability to lead structured discovery with non-technical business owners and translate requirements into PRDs, SDDs, and test plans across the full SDLC.
- Comfort with Workday Report Writer, EIB, and structured data.
- Demonstrated experience evaluating and deploying AI and LLM tools.
- Familiarity with low-code automation tools such as n8n, Zapier, and Cowork.
- Familiarity with responsible AI governance.
- A track record of using listening data to drive measurable improvements.
- Proven ability to build credibility across IT, Finance, Legal, and Talent Acquisition.
- Candidates must be based in the San Francisco Bay Area and be available to work regularly from the San Francisco and Palo Alto offices.
- Serve as the primary functional administrator and HRIS product owner for Workday HCM across Core, Compensation, Talent, Absence, and Benefits.
- Own the People systems software development life cycle end-to-end, from requirements through user acceptance testing sign-off, Go/No-Go, hypercare, and project closure.
- Lead structured requirements gathering with business owners across People, Finance, Legal, and Talent Acquisition, translating requirements into PRDs, process flows, and formal test plans.
- Manage semi-annual Workday release cycles, including feature evaluation, impact assessment, testing coordination, and change communication.
- Own the enhancement intake and prioritization pipeline and maintain a versioned requirements library across all People systems.
- Monitor and maintain People system integrations across Workday, Greenhouse, VNDLY, payroll, benefits, and ServiceNow, targeting a month-over-month error rate below 1%.
- Serve as the named HR Business Process Owner in SOX documentation and co-approve in-scope change evidence with the IT System Owner.
- Maintain user access controls, segregation-of-duties controls, and user access review evidence across all audit cycles.
- Contribute to the team's AI innovation agenda by evaluating and deploying AI-native tools and LLM-based automations across the HR technology stack.
- Architect AI-powered workflows in Moveworks/Maverick and Databricks and build data pipelines from Workday, Greenhouse, and ADP to support workforce planning and analytics.
- Own the Maverick People Assistant implementation, including service catalog design, CMS authoring standards, agentic workflow configuration, and the Moveworks-to-ServiceNow integration layer.
- Govern all AI deployments through a responsible AI framework covering fairness, data privacy, compliance, auditability, and human oversight before production.
- Design People systems from the employee perspective by mapping the full HR journey, identifying friction points, and ensuring configuration produces an intuitive, consistent experience.
- Own the HR service catalog by defining each People team service, its delivery channel, SLA, and experience metrics.
- Architect the self-service channel strategy across Workday, ServiceNow, and the AI People bot and measure containment rate and time-to-resolution as primary KPIs.
- Own Greenhouse ATS configuration end-to-end, including pipeline architecture, interview kits, scorecards, offer workflows, and data hygiene.
- Manage the Greenhouse-to-Workday integration to eliminate manual rekeying from offer acceptance through Day 1 provisioning.
- Own the VNDLY contingent workforce platform, including onboarding/offboarding workflows, tenure monitoring, classification controls, and Workday record synchronization.
- Databricks and SQL experience for people analytics pipelines.
- Hands-on Moveworks or equivalent conversational AI platform experience, including agent configuration, intent taxonomy, and retrieval-augmented generation.
BridgeBio Pharma develops medicines for genetic diseases through a decentralized subsidiary model, with each subsidiary focused on a specific disease while sharing central resources. It advances multiple drug programs at once by using genome sequencing, molecular biology, and patient data to identify targets and translate research into therapies. Therapies target the underlying genetic causes to create disease-modifying treatments, and BridgeBio monetizes via licensing, partnerships, and eventual commercialization of approved drugs. The company differentiates itself by its independent subsidiaries with centralized support, data-driven decision making, and a culture of radical transparency, all to accelerate discovery and bring therapies to patients faster.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2014
Get referred to BridgeBio
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $243.7 million; Attruby sales hit $222.4 million.
- Attruby first-half 2026 sales reached $403 million, with treatment-naive share still rising.
- ENCAleret and infigratinib are under FDA review, creating multiple launch catalysts through 2027.
What critics are saying
- Attruby concentration is extreme; any reimbursement or safety slip before 2027 crushes growth.
- BBP-418 faces a November 27, 2026 FDA decision; a CRL would damage credibility.
- Tafamidis remains the entrenched ATTR-CM rival; payers can force step-edits and slow switching.
What makes BridgeBio unique
- Acoramidis/Attruby is approved globally and showed 54-month survival benefit at ESC 2026.
- BridgeBio’s decentralized model pushes three NDAs simultaneously: BBP-418, encaleret, infigratinib.
- BBP-418 could become the first approved therapy for LGMD2I/R9, per May 2026 FDA filing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Performance Bonus
Company Equity
Unlimited Paid Time Off
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -3%2 year growth
↑ 1%Lionsbridge Wealth Management LLC acquired a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,453 shares of the company’s stock, valued at approximately $704,000. A number of […]
BridgeBio to present new data on the impact of Oral Infigratinib on medical complications in achondroplasia at the Annual ESPE Meeting 2026. PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia from PROPEL 3 will be shared at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, taking place in Marseille, France on September 8-10, 2026. In addition to the late-breaking oral presentation, two posters and one eposter will be shared on longer-term data for oral infigratinib in achondroplasia, PROPEL I&T-an ongoing Phase 2/2b study in children under 3 years old with achondroplasia, and qualitative research on the impacts of hypochondroplasia. BridgeBio is committed to exploring the potential of oral infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia and other skeletal dysplasia conditions, which hold significant unmet needs for families. Late-Breaking Oral Presentation: A Randomized Controlled Trial of Oral Infigratinib in Children with Achondroplasia: Results from the PROPEL 3 Study Presenter: Julie Hoover-Fong, M.D., Ph.D., Johns Hopkins University, U.S. Date: Wednesday, September 9 at 10:00 am CEST Posters: Longer-Term Efficacy and Safety Results of Infigratinib in Children with Achondroplasia Presenter: Melita Irving, M.D., Guy's and St Thomas' NHS Foundation Trust, London, UK PROPEL Infant and Toddler: Study Design and Ongoing Enrollment of a Phase 2/2b Study of Infigratinib in Children under 3 Years Old with Achondroplasia Presenter: Melita Irving, M.D., Guy's and St Thomas' NHS Foundation Trust, London, UK ePoster: Potential Medical Challenges and Functional Impacts of Hypochondroplasia: Qualitative Interviews with Children and Parents Presenter: Melita Irving, M.D., Guy's and St Thomas' NHS Foundation Trust, London, UK About Achondroplasia Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the U.S. and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating variant in FGFR3. About Oral Infigratinib Oral infigratinib is an investigational small molecule designed to inhibit FGFR3 signaling and target skeletal dysplasias, including achondroplasia and hypochondroplasia, at their source. Overactivating FGFR3 pathogenic variants drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and the potential for serious health complications. Oral infigratinib improves bone growth by decreasing the overactivity of FGFR3. About BridgeBio BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. Africa Daily Journal aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Its decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow Africa Daily Journal on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok. BridgeBio Media Contact: Kaitlyn Reilly, Director, Communications [email protected] (650) 789-8220 BridgeBio Investor Contact: Kristen Kelleher, Director, Investor Relations [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa Daily Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
BridgeBio Pharma presented new analyses from its Phase 3 ATTRibute-CM study of Attruby (acoramidis) for transthyretin amyloid cardiomyopathy at the European Society of Cardiology Congress 2026. The findings were simultaneously published in the European Journal of Heart Failure. Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging. Up to half of patients showed clinically meaningful improvement in cardiac function in the completer analysis. Patients treated with acoramidis had 65 additional days alive and out of hospital by Month 36 versus baseline placebo patients. The drug demonstrated long-term efficacy and safety through 54 months across variant ATTR-CM subgroups. Acoramidis is an orally administered, near-complete transthyretin stabiliser.
BridgeBio Pharma shares have risen 24% in the past three months, significantly outperforming the S&P 500's 0.7% gain over the same period. The rally extends a 71.4% advance over the past year. Attruby generated $403 million in US sales during the first half of 2026, following $362.4 million in 2025. The drug continued gaining share among treatment-naive patients whilst diagnosed ATTR-CM patients in the United States exceeded 50,000 in 2025. The company faces an FDA decision for BBP-418 by 27 November 2026, with additional regulatory decisions expected for encaleret on 8 May 2027 and infigratinib in early to mid-2027. BBIO trades at 12 times forward enterprise value-to-sales, compared with 2.9 times for its industry peers.
BridgeBio joins CardioHealth Alliance as a new life science partner to advance evidence-based prevention and care. Posted on August 24, 2026 by A M The CardioHealth Alliance welcomes BridgeBio as a new life science partner, further strengthening the Alliance's work to advance evidence-based solutions for the prevention and care of cardiovascular, renal, and metabolic diseases. BridgeBio is a biopharmaceutical company focused on developing transformative medicines for patients with genetic diseases, like transthyretin amyloid cardiomyopathy (ATTR-CM). Through its support of the CardioHealth Alliance, BridgeBio will help advance collaborative efforts to address gaps in cardiovascular care and accelerate the translation of research insights into real-world practice. "BridgeBio was founded to close the gap between genetic discovery and patient care, and cardiovascular disease is where this gap can cost the most lives. Closing this gap requires the kind of cross-disciplinary innovation and collaboration the CardioHealth Alliance was built for. Joining the CardioHealth Alliance will help BridgeBio strengthen the evidence base for turning clinical insight into standard practice." - Jennifer Hodge, PhD, Vice President, Evidence Generation, BridgeBio Established by leaders from the Duke Clinical Research Institute and the Stanford Center for Clinical Research in 2020, the CardioHealth Alliance engages clinicians, data scientists, health care leaders, and policy makers to improve disease care pathways and expedite the implementation of evidence into practice. BridgeBio joins this multidisciplinary group of experts across 13 health systems and five life science partners who are working together to * Use real-world data to inform real-world care * Develop and test new pathways and practices * Scale and optimize best practices * Continuously address value of care through effective policy The Alliance will continue to leverage partnerships with large health systems, academic institutions, and life science partners, including BridgeBio, to manage a broad portfolio of research focused on improving care delivery and outcomes across cardiometabolic conditions. The collaboration aims to address major public health concerns by helping evidence-based therapies and care approaches become integrated into real-world clinical practice. "To accelerate progress in clinical care for people with heart disease, we must embrace a collaborative, cross-disciplinary approach that fosters innovation in how we study health and apply new insights," said Javed Butler, MD, MPH, MBA, Alliance Executive Committee Co-Chair; President, Baylor Scott & White Research Institute; and Senior vice president, Baylor Scott & White Health. "By drawing on the shared expertise of our partners in the CardioHealth Alliance, we can deliver data-informed solutions more quickly to the patients who need them most."